Qinlock
| Chemical Name | ripretinib |
| Dosage Form | Tablet (oral; 50 mg) |
| Drug Class | Kinase inhibitors |
| System | Multiple |
| Company | Deciphera Pharmaceuticals |
| Approval Year | 2020 |
Indication
- For the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.